Neovasc Inc.

Recent News

  • Neovasc to Participate in Sidoti December Virtual Microcap Conference

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 1, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that its management team will be participating in the Sidoti December Virtual Microcap Conference to be held December 8-9, 2021. Fred Colen, President and Chief Executive Officer, will give a presentation on Wednesday, December 8 at 3:15 pm EST. A link to the live webcast of the presentation will be available in the Investor...

    2021-12-01 9:05 AM EST
  • Neovasc Reducer(TM) System Receives National Reimbursement in France

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 30, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Neovasc Reducer™ ("Reducer") system has been granted Prise en Charge Transitoire ("PECT") reimbursement in France by the national health authority, Haute Autorité de Santé ("HAS"). The decision will be officialized upon publication in the French Journal Officiel.The Reducer is the first therapy to be approved under the newly established PECT process. It is designed to allow patients...

    2021-11-30 9:51 AM EST
  • Neovasc Granted Additional 180 Calendar Day Grace Period for Nasdaq Bid Price Compliance

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 24, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that in accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq has granted an additional 180 calendar day period within which to evidence compliance with the $1.00 bid price requirement following the expiration of the current compliance period on November 22, 2021.The Nasdaq Notice does...

    2021-11-24 1:24 PM EST
  • The National Institute for Health and Care Excellence of the United Kingdom Provides Positive Guidance for Neovasc Reducer System

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 24, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the United Kingdom's Interventional Procedures Programme at the National Institute for Health and Care Excellence ("NICE") has issued guidance supporting the implantation of the Neovasc Reducer™ ("Reducer") in appropriate patients suffering from refractory angina, a painful and debilitating condition that causes chest pain when other treatment options have failed or are not possible.NICE's current guideline on...

    2021-11-24 9:29 AM EST
  • Neovasc Announces Third Quarter 2021 Financial Results and Provides Corporate Update

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 9, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the third quarter ended September 30, 2021. Third Quarter HighlightsStrong progress against all three value creation strategies.Generated record revenue of approximately $703,000 in the quarter, up 12% from the same period in 2020.Advanced strategic focus to obtain additional reimbursement for the Neovasc ReducerTM in multiple EU countries and the United States. Continued preparations...

    2021-11-09 4:05 PM EST
  • Neovasc to Report Third Quarter 2021 Financial Results on November 9, 2021

    Vancouver, British Columbia--(Newsfile Corp. - November 1, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended September 30, 2021 on Tuesday, November 9, 2021. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on November 9, 2021.Interested parties may access the conference call by dialing (877)-407-9208 or (201)-493-6784 (International) and reference Conference ID 13723809....

    2021-11-01 9:05 AM EDT
  • Neovasc Reducer(TM) Featured in Polish Heart Journal

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 21, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN)  ("Neovasc" or the "Company") today announced that the Neovasc Reducer™ ("Reducer") is featured in an article published in the latest issue of the Polish Heart Journal. Entitled "Efficacy of Coronary Sinus Reducer Implantation in Patients with Chronic Total Occlusion of the Right Coronary Artery," the article's first author is Miha Mrak, M.D., University Medical Centre Ljubljana, Ljubljana, Slovenia.The publication provides new information relating to...

    2021-10-21 9:05 AM EDT
  • Neovasc REDUCER-I Study Published in EuroIntervention Journal

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 28, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the publication of an article entitled, "Coronary sinus narrowing for the treatment of refractory angina: a multicentre prospective open-label clinical study (the REDUCER-I study)" in the September 2021 issue of the journal EuroIntervention.The article's lead authors are Stefan Verheye, MD, PhD, Cardiovascular Center, ZNA Middelheim Hospital, Antwerp, Belgium, and Maayan Konigstein, MD, from the Tel Aviv Medical...

    2021-09-28 9:05 AM EDT